Evidence map›Paper›PMID 34500564›Full record

ArticleMolecules (Basel, Switzerland)2021

ST-2191, an Anellated Bismorpholino Derivative of Oxy-Fingolimod, Shows Selective S1P

Bisera Stepanovska Tanturovska, Aleksandra Zivkovic, Faik Imeri, Thomas Homann, Burkhard Kleuser, Holger Stark, Andrea Huwiler

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Bisera Stepanovska TanturovskaInstitute of Pharmacology, University of Bern, Inselspital INO-F, CH-3010 Bern, Switzerland.
Aleksandra ZivkovicInstitute of Pharmaceutical and Medicinal Chemistry, Heinrich Heine University Düsseldorf, Universitaetsstr. 1, D-40225 Duesseldorf, Germany.
Faik ImeriInstitute of Pharmacology, University of Bern, Inselspital INO-F, CH-3010 Bern, Switzerland.
Thomas HomannInstitute of Nutritional Science, University of Potsdam, Arthur-Scheunert Allee 114-116, D-14558 Nuthetal, Germany.
Burkhard KleuserInstitute of Pharmacy, Freie Universität Berlin, Königin-Luise-Str. 2+4, D-14195 Berlin, Germany.ORCID 0000-0002-1888-9595
Holger StarkInstitute of Pharmaceutical and Medicinal Chemistry, Heinrich Heine University Düsseldorf, Universitaetsstr. 1, D-40225 Duesseldorf, Germany.ORCID 0000-0003-3336-1710
Andrea HuwilerInstitute of Pharmacology, University of Bern, Inselspital INO-F, CH-3010 Bern, Switzerland.ORCID 0000-0003-1615-5691
University of Bern · CHHeinrich Heine University Düsseldorf · DEFreie Universität Berlin · DEUniversity of Potsdam · DE

Funding

Deutsche Forschungsgemeinschaft GRK2158, INST 208/690-1European Cooperation in Science and Technology CA15135, CA18133, CA18240Hochschulstiftung der Universität Bern 20/2020Schweizerische Multiple Sklerose Gesellschaft n.a.Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung 310030_135619
6 · The paper itself

Abstract

Sphingosine 1-phosphate (S1P) is an extensively studied signaling molecule that contributes to cell proliferation, survival, migration and other functions through binding to specific S1P receptors. The cycle of S1P

Indexed as

AnimalsCHO CellsCricetulusFingolimod HydrochlorideHumansLymphocyte CountLysophospholipidsMiceMice, Inbred C57BLMultiple SclerosisPhosphotransferases (Alcohol Group Acceptor)Receptors, LysosphingolipidSignal TransductionSphingosineT-LymphocytesFingolimod HydrochlorideLysophospholipidsPhosphotransferases (Alcohol Group Acceptor)Receptors, LysosphingolipidSphingosinesphingosine 1-phosphateanellated bismorpholinofunctional antagonismlymphopeniaS1P1 receptorsphingosine 1-phosphateST-2191

Identifiers

PMID34500564
PMCPMC8433829
OpenAlexW3194371582

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.